lumefantrine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1617 | 82186-77-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Lumefantrine is an antimalarial agent. Available data suggest lumefantrine inhibits the formation of beta-hematin by forming a complex with hemin.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.28 | g | O |
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 7, 2009 | FDA | NOVARTIS |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | P01BF01 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS ANTIMALARIALS Artemisinin and derivatives, combinations |
| FDA EPC | N0000175482 | Antimalarial |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000962 | Antimalarials |
| MeSH PA | D000977 | Antiparasitic Agents |
| MeSH PA | D000981 | Antiprotozoal Agents |
| CHEBI has role | CHEBI:38068 | antimalarials |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Falciparum malaria | indication | 62676009 | DOID:14067 |
| Torsades de pointes | contraindication | 31722008 | |
| Hypokalemia | contraindication | 43339004 | |
| Bradycardia | contraindication | 48867003 | |
| Prolonged QT interval | contraindication | 111975006 | |
| Hypomagnesemia | contraindication | 190855004 | |
| Congenital long QT syndrome | contraindication | 442917000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.94 | acidic |
| pKa2 | 8.77 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.09 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4028722 | VUID |
| N0000178418 | NUI |
| D03821 | KEGG_DRUG |
| 4028722 | VANDF |
| C0531104 | UMLSCUI |
| CHEBI:156095 | CHEBI |
| CHEMBL422330 | ChEMBL_ID |
| CHEMBL38827 | ChEMBL_ID |
| D000078102 | MESH_DESCRIPTOR_UI |
| DB06708 | DRUGBANK_ID |
| 9969 | IUPHAR_LIGAND_ID |
| 7610 | INN_ID |
| F38R0JR742 | UNII |
| 6437380 | PUBCHEM_CID |
| 847728 | RXNORM |
| 18118 | MMSL |
| d05144 | MMSL |
| 009715 | NDDF |
| 420307001 | SNOMEDCT_US |
| 421180001 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| COARTEM | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0078-0568 | TABLET | 120 mg | ORAL | NDA | 28 sections |
| COARTEM | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0078-0568 | TABLET | 120 mg | ORAL | NDA | 28 sections |
| COARTEM | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0078-0568 | TABLET | 120 mg | ORAL | NDA | 28 sections |
| COARTEM | HUMAN PRESCRIPTION DRUG LABEL | 2 | 76413-154 | TABLET | 120 mg | ORAL | NDA | 27 sections |